Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
Piramal Pharma Limited has acquired an additional 40.67% stake in Yapan Bio Private Limited for 76 crore rupees, bringing its total ownership to 74%. This move aims to bolster Piramal's biologics and vaccine manufacturing capabilities within its CDMO division.
Why it matters
This acquisition strengthens the pharmaceutical supply chain for complex biologic therapies and accelerates drug development timelines.
MUMBAI, India , Aug. 18, 2026 /PRNewswire/ -- Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ("Yapan Bio"), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore, or $7.95M USD. As a result of this transaction, PPL now owns 74% of Yapan Bio's equity, making Yapan Bio a subsidiary of PPL.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in